Exact Sciences, a provider of cancer screening and diagnostic tests, completed the acquisition of Paradigm and Viomics, providers of a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery. Financial terms were not disclosed. "The addition of these companies and their talented team members to Exact Sciences is another step forward in extending our leadership in advanced cancer diagnostics. Viomics' research capabilities and the Paradigm therapy selection test and scalable clinical lab, combined with the powerful Exact Sciences commercial platform, allow us to provide patients with smarter, faster answers throughout the cancer continuum," Kevin Conroy, Exact Sciences Chairman and CEO.